menu
    • menu
    [{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Genzum Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genzum Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genzum Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genzum Life Sciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for naftifine hydrochloride

    Menu

    naftifine hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of NAFT900 in Children With Tinea Capitis

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tinea Capitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2016

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genzum Life Sciences

                            Country arrow
                            COMPAMED
                            Not Confirmed

                            Genzum Life Sciences

                            Country arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BE Study of Naftifine HCL

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 17, 2015

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tinea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2015

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 09, 2015

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pediatric Subjects With Tinea Corporis

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tinea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2014

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With ...

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2014

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tinea Cruris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 24, 2013

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 23, 2012

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis

                            Details : Naftifine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 19, 2012

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

                            Details : Naftin (Naftifine HCl) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tinea Pedis.

                            Product Name : Naftin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 07, 2011

                            Lead Product(s) : NAFTIFINE HCL

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth